Raloxifene is a selective estrogen receptor modulator (SERM) primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer.… Read more












































Raloxifene is a selective estrogen receptor modulator (SERM) primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer. As an estrogen agonist in bone tissue, it helps maintain bone mineral density, while acting as an antagonist in breast and uterine tissues. To ensure the safety and efficacy of this therapeutic agent, pharmaceutical laboratories rely on a comprehensive range of Raloxifene reference standards. This category includes process-related impurities, synthetic intermediates, degradation products, and metabolites such as glucuronides, as well as stable isotope labelled compounds. These materials are essential for rigorous impurity profiling, stability-indicating method validation, and consistent quality control throughout the drug manufacturing lifecycle. By providing precise benchmarks for analytical testing, these standards support adherence to global regulatory requirements and help maintain the integrity of pharmaceutical analysis.